GB9501841D0
(en)
*
|
1995-01-31 |
1995-03-22 |
Co Ordinated Drug Dev |
Improvements in and relating to carrier particles for use in dry powder inhalers
|
GB9515182D0
(en)
*
|
1995-07-24 |
1995-09-20 |
Co Ordinated Drug Dev |
Improvements in and relating to powders for use in dry powder inhalers
|
GB9703673D0
(en)
*
|
1997-02-21 |
1997-04-09 |
Bradford Particle Design Ltd |
Method and apparatus for the formation of particles
|
US20070212422A1
(en)
*
|
1999-11-10 |
2007-09-13 |
Manfred Keller |
Dry powder for inhalation
|
US20060171899A1
(en)
*
|
1998-12-10 |
2006-08-03 |
Akwete Adjei |
Water-stabilized aerosol formulation system and method of making
|
IT1309592B1
(it)
*
|
1999-03-05 |
2002-01-24 |
Chiesi Farma Spa |
Particelle veicolo modificate da utilizzarsi nella preparazione diformulazioni farmaceutiche sotto forma di polimeri per inalazione e
|
PT1158958E
(pt)
*
|
1999-03-05 |
2007-08-13 |
Chiesi Farma Spa |
''composições farmacêuticas em pó, melhoradas, para inalação''
|
GB0009468D0
(en)
*
|
2000-04-17 |
2000-06-07 |
Vectura Ltd |
Improvements in or relating to formulations for use in inhaler devices
|
GB0009469D0
(en)
*
|
2000-04-17 |
2000-06-07 |
Vectura Ltd |
Improvements in or relating to formalities for use in inhaler devices
|
PE20011227A1
(es)
*
|
2000-04-17 |
2002-01-07 |
Chiesi Farma Spa |
Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
|
GB0012260D0
(en)
|
2000-05-19 |
2000-07-12 |
Astrazeneca Ab |
Novel composition
|
GB0012261D0
(en)
|
2000-05-19 |
2000-07-12 |
Astrazeneca Ab |
Novel process
|
KR100949539B1
(ko)
|
2000-06-27 |
2010-03-25 |
벡투라 리미티드 |
약학 조성물용 입자의 제조 방법
|
GB0027357D0
(en)
|
2000-11-09 |
2000-12-27 |
Bradford Particle Design Plc |
Particle formation methods and their products
|
EP1920763B2
(fr)
|
2000-11-30 |
2022-06-15 |
Vectura Limited |
Compositions pharmaceutiques pour l'inhalation
|
ES2689704T3
(es)
*
|
2000-11-30 |
2018-11-15 |
Vectura Limited |
Partículas para usar en una composición farmacéutica
|
EP1337241B1
(fr)
†
|
2000-11-30 |
2008-01-02 |
Vectura Limited |
Méthode pour la preparation des microparticles à utiliser dans des compositions pharmaceutiques pour inhalation
|
WO2002056948A1
(fr)
|
2001-01-17 |
2002-07-25 |
Vectura Limited |
Dispositif d'inhalation
|
GB0208742D0
(en)
|
2002-04-17 |
2002-05-29 |
Bradford Particle Design Ltd |
Particulate materials
|
AU2002333644A1
(en)
|
2001-09-17 |
2003-04-01 |
Glaxo Group Limited |
Dry powder medicament formulations
|
US7931533B2
(en)
|
2001-09-28 |
2011-04-26 |
Igt |
Game development architecture that decouples the game logic from the graphics logics
|
SE0200312D0
(sv)
|
2002-02-01 |
2002-02-01 |
Astrazeneca Ab |
Novel composition
|
US20050191357A1
(en)
*
|
2002-03-20 |
2005-09-01 |
Yoshiaki Kawashima |
Method of manufacturing chemical-containing composite particles
|
FI116657B
(fi)
*
|
2002-03-28 |
2006-01-31 |
Focus Inhalation Oy |
Menetelmä kantoainehiukkasten käsittelemiseksi ja niiden käyttö
|
US20030235538A1
(en)
*
|
2002-04-09 |
2003-12-25 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Method for the administration of an anticholinergic by inhalation
|
US7582284B2
(en)
*
|
2002-04-17 |
2009-09-01 |
Nektar Therapeutics |
Particulate materials
|
GB0216562D0
(en)
|
2002-04-25 |
2002-08-28 |
Bradford Particle Design Ltd |
Particulate materials
|
US9339459B2
(en)
|
2003-04-24 |
2016-05-17 |
Nektar Therapeutics |
Particulate materials
|
EP1599209B1
(fr)
*
|
2002-08-21 |
2011-08-17 |
Norton Healthcare Limited |
Compositions a inhaler
|
WO2004028545A1
(fr)
*
|
2002-09-25 |
2004-04-08 |
Astrazeneca Ab |
Combinaison d'un agoniste $g(b)2 a action prolongee et d'un glucocorticosteroide dans le traitement de maladies fibrotiques
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
EP1452179A1
(fr)
*
|
2003-02-27 |
2004-09-01 |
CHIESI FARMACEUTICI S.p.A. |
Nouveau combination d'un puissant agoniste beta 2 de longue duree et un corticosteroid
|
US20060147389A1
(en)
*
|
2004-04-14 |
2006-07-06 |
Vectura Ltd. |
Devices and pharmaceutical compositions for enhancing dosing efficiency
|
AU2004231342A1
(en)
*
|
2003-04-14 |
2004-11-04 |
Vectura Ltd |
Dry power inhaler devices and dry power formulations for enhancing dosing efficiency
|
US7094545B2
(en)
*
|
2003-04-30 |
2006-08-22 |
Ferring Bv |
Pharmaceutical composition as solid dosage form and method for manufacturing thereof
|
EP1646370A1
(fr)
*
|
2003-07-11 |
2006-04-19 |
Glaxo Group Limited |
Formulations pharmaceutiques
|
EP1643973A1
(fr)
*
|
2003-07-11 |
2006-04-12 |
Glaxo Group Limited |
Preparations pharmaceutiques contenant du stearate de magnesium
|
CN1826099B
(zh)
*
|
2003-07-25 |
2010-06-09 |
凡林有限公司 |
固体剂型药物组合物及其制造方法
|
EP1500390B1
(fr)
*
|
2003-07-25 |
2005-08-17 |
Ferring B.V. |
Composition pharmaceutique comprenant du desmopressin comme forme galénique solide et procédé de fabrication
|
GB0321607D0
(en)
*
|
2003-09-15 |
2003-10-15 |
Vectura Ltd |
Manufacture of pharmaceutical compositions
|
GB0327723D0
(en)
|
2003-09-15 |
2003-12-31 |
Vectura Ltd |
Pharmaceutical compositions
|
US20060292081A1
(en)
*
|
2003-09-15 |
2006-12-28 |
Vectura Limited |
Methods for preparing pharmaceutical compositions
|
GB0324918D0
(en)
*
|
2003-10-24 |
2003-11-26 |
Glaxo Group Ltd |
Composition
|
GB0326632D0
(en)
*
|
2003-11-14 |
2003-12-17 |
Jagotec Ag |
Dry powder formulations
|
SE0303570L
(sv)
*
|
2003-12-03 |
2005-06-04 |
Microdrug Ag |
Fukt-känslig medicinsk produkt
|
EP1691782A1
(fr)
*
|
2003-12-03 |
2006-08-23 |
Microdrug AG |
Produit medical contenant du tiotropium
|
SE0303269L
(sv)
*
|
2003-12-03 |
2005-06-04 |
Microdrug Ag |
Medicinsk produkt
|
SE0303571D0
(sv)
*
|
2003-12-03 |
2003-12-22 |
Microdrug Ag |
Medical product for moisture-sensitive medicaments
|
SE0303270L
(sv)
*
|
2003-12-03 |
2005-06-04 |
Microdrug Ag |
Metod för administration av tiotropium
|
SE0303569L
(sv)
*
|
2003-12-03 |
2005-06-04 |
Microdrug Ag |
DPI för avlämning av fuktkänsliga medikament
|
US7018653B2
(en)
|
2003-12-29 |
2006-03-28 |
Ferring B.V. |
Method for preparing solid dosage form of desmopressin
|
JO3102B1
(ar)
*
|
2004-03-17 |
2017-09-20 |
Chiesi Framaceutici S P A |
صيغ صيدلانية لوسائل استنشاق بها مسحوق جاف تشتمل على مكون فعال بقوة منخفضة الجرعة
|
RU2006141358A
(ru)
*
|
2004-04-23 |
2008-05-27 |
Сайдекс, Инк. (Us) |
Препаративная форма для ингалятора сухого порошка, содержащая простой сульфоалкиловый эфир циклодекстрина
|
GB0409703D0
(en)
|
2004-04-30 |
2004-06-02 |
Vectura Ltd |
Pharmaceutical compositions
|
GB0425758D0
(en)
*
|
2004-11-23 |
2004-12-22 |
Vectura Ltd |
Preparation of pharmaceutical compositions
|
GB0426301D0
(en)
*
|
2004-11-30 |
2004-12-29 |
Vectura Ltd |
Pharmaceutical formulations
|
RU2007133547A
(ru)
|
2005-02-10 |
2009-03-20 |
Глаксо Груп Лимитед (GB) |
Способы получения лактозы с использованием методов предварительной сортировки и приготовляемые из нее фармацевтические композиции
|
KR20070110418A
(ko)
*
|
2005-03-09 |
2007-11-16 |
오노 야꾸힝 고교 가부시키가이샤 |
입자 및 그 입자를 함유하는 제제
|
WO2006105401A2
(fr)
*
|
2005-03-30 |
2006-10-05 |
Schering Corporation |
Medicaments et procedes de combinaison d'un anticholinergique, un corticosteroide, et un agoniste beta a action prolongee
|
TWI274641B
(en)
*
|
2005-08-30 |
2007-03-01 |
Rexon Ind Corp Ltd |
Cutting machine
|
US7629331B2
(en)
|
2005-10-26 |
2009-12-08 |
Cydex Pharmaceuticals, Inc. |
Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
|
GB0525254D0
(en)
|
2005-12-12 |
2006-01-18 |
Jagotec Ag |
Powder compositions for inhalation
|
GB0613161D0
(en)
*
|
2006-06-30 |
2006-08-09 |
Novartis Ag |
Organic Compounds
|
GB0622818D0
(en)
*
|
2006-11-15 |
2006-12-27 |
Jagotec Ag |
Improvements in or relating to organic compounds
|
EP1944018A1
(fr)
*
|
2007-01-10 |
2008-07-16 |
CHIESI FARMACEUTICI S.p.A. |
Particules micronisées comprenant des principes actifs agissant même à faible dose pour préparations en poudre pour inhalation
|
WO2008097664A1
(fr)
*
|
2007-02-11 |
2008-08-14 |
Map Pharmaceuticals, Inc. |
Procédé d'administration thérapeutique de dhe pour procurer un soulagement rapide de la migraine tout en minimisant le profil des effets secondaires
|
JP2010534248A
(ja)
|
2007-07-21 |
2010-11-04 |
アルバニー モレキュラー リサーチ, インコーポレイテッド |
5−ピリジノン置換インダゾール
|
EP2222639A1
(fr)
|
2007-11-21 |
2010-09-01 |
Decode Genetics EHF |
Inhibiteurs de biaryle pde4 pour le traitement de troubles pulmonaires et cardiovasculaires
|
ES2523580T3
(es)
|
2008-01-11 |
2014-11-27 |
Albany Molecular Research, Inc. |
Piridoindoles substituidos con (1-Azinona)
|
EP2292089A1
(fr)
|
2008-01-11 |
2011-03-09 |
Astellas Pharma Inc. |
Modèle animal ayant à la fois une douleur dans les testicules ou des actions d'inconfort en relation aux testicules et une miction fréquente
|
EP2080508A1
(fr)
|
2008-01-15 |
2009-07-22 |
CHIESI FARMACEUTICI S.p.A. |
Formulation de poudre sèche comprenant un médicament anticholinérgique
|
WO2010059836A1
(fr)
|
2008-11-20 |
2010-05-27 |
Decode Genetics Ehf |
Composés bicycliques substitués à pont aza pour maladie cardiovasculaire et du système nerveux central
|
EP2191821A1
(fr)
*
|
2008-11-26 |
2010-06-02 |
CHIESI FARMACEUTICI S.p.A. |
Microparticles contenant une sel de 8-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone avec adhesion ameliorée pour l'inhalation de poudre sèche
|
RU2506266C2
(ru)
|
2009-01-26 |
2014-02-10 |
Израэл Инститьют Фо Байолоджикал Рисерч |
Бициклические гетероциклические спиросоединения
|
US9925282B2
(en)
|
2009-01-29 |
2018-03-27 |
The General Hospital Corporation |
Cromolyn derivatives and related methods of imaging and treatment
|
WO2010097188A1
(fr)
*
|
2009-02-25 |
2010-09-02 |
Chiesi Farmaceutici S.P.A. |
Particules pour inhalation comprenant un sel de carmotérol et un corticostéroïde
|
ES2739352T3
(es)
|
2009-02-26 |
2020-01-30 |
Glaxo Group Ltd |
Formulaciones farmacéuticas que comprenden 4-{(1R)-2-[(6-{2-[(2,6-diclorobencil)oxi]etoxi}hexil)amino]-1-hidroxietil}-2-(hidroximetil)fenol
|
MX2011011123A
(es)
*
|
2009-04-24 |
2011-11-04 |
Schering Corp |
Formulaciones de aglomerado utiles en inhaladores de polvo seco.
|
WO2011015289A1
(fr)
|
2009-08-04 |
2011-02-10 |
Chiesi Farmaceutici S.P.A. |
Hémi-fumarate de 8-hydroxy-5-[(1r)-1-hydroxy-2-[[(1r)-2- (4-méthoxyphényl)-1-méthyléthyl]amino]éthyl]-2(1h)-quinolinone
|
GB0918249D0
(en)
|
2009-10-19 |
2009-12-02 |
Respivert Ltd |
Compounds
|
GB0921075D0
(en)
|
2009-12-01 |
2010-01-13 |
Glaxo Group Ltd |
Novel combination of the therapeutic agents
|
EP2360147A1
(fr)
|
2010-02-22 |
2011-08-24 |
CHIESI FARMACEUTICI S.p.A. |
Procédé de préparation de particules crystallines d'un sel de 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino] ethyl]-2(1H)-quinolinone (carmoterol)
|
WO2011120779A1
(fr)
|
2010-04-01 |
2011-10-06 |
Chiesi Farmaceutici S.P.A. |
Procédé de préparation de particules d'excipient pour poudres sèches à inhaler
|
EP2560611B1
(fr)
*
|
2010-04-21 |
2018-01-03 |
Chiesi Farmaceutici S.p.A. |
Procédé de préparation de particules ayant des charges électrostatiques réduites
|
AU2011245117B2
(en)
|
2010-04-30 |
2015-03-12 |
Alexion Pharmaceuticals, Inc. |
Anti-C5a antibodies and methods for using the antibodies
|
EP2575786B1
(fr)
|
2010-06-03 |
2017-11-15 |
Sima Patent ve Lisanslama Hizmetleri Ltd.Sti. |
Procédé pour formulations pulvérulentes sèches
|
WO2011160920A1
(fr)
*
|
2010-06-22 |
2011-12-29 |
Chiesi Farmaceutici S.P.A. |
Formulation de poudre sèche comprenant un médicament antimuscarinique
|
MA34449B1
(fr)
*
|
2010-08-03 |
2013-08-01 |
Chiesi Farma Spa |
Formulation de poudre seche comprenant un inhibiteur de phosphodiesterase
|
EP2611416B1
(fr)
*
|
2010-09-03 |
2015-08-19 |
Pharmaterials Ltd. |
Composition pharmaceutique pour l'utilisation avec un inhalateur de poudre seche
|
KR101915241B1
(ko)
|
2010-09-29 |
2018-11-06 |
풀매트릭스 오퍼레이팅 컴퍼니, 인크 |
흡입용의 1가 금속 양이온 건조 분말
|
WO2012041717A1
(fr)
|
2010-09-30 |
2012-04-05 |
Chiesi Farmaceutici S.P.A. |
Utilisation de stéarate de magnésium dans des préparations en poudre sèche destinées à être inhalées
|
UY33337A
(es)
|
2010-10-18 |
2011-10-31 |
Respivert Ltd |
DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
|
US9808030B2
(en)
|
2011-02-11 |
2017-11-07 |
Grain Processing Corporation |
Salt composition
|
TR201105367A2
(tr)
*
|
2011-06-02 |
2012-12-21 |
Bi̇lgi̇ç Mahmut |
Akış özellikleri geliştirilmiş bir kuru toz formülasyonu.
|
TR201205852A2
(tr)
*
|
2011-06-02 |
2012-12-21 |
Bi̇lgi̇ç Mahmut |
Geliştirilmiş yeni kuru toz formülasyonu.
|
WO2013109215A1
(fr)
*
|
2012-01-16 |
2013-07-25 |
Mahmut Bilgic |
Préparation de formulations en poudre sèche comprenant du formotérol
|
WO2013109210A1
(fr)
*
|
2012-01-16 |
2013-07-25 |
Mahmut Bilgic |
Formulations en poudre sèche comprenant du budésonide
|
EP2804583A1
(fr)
*
|
2012-01-16 |
2014-11-26 |
Mahmut Bilgic |
Formulations en poudre sèche comprenant du r-formotérol utilisé comme agent actif
|
RS63706B1
(sr)
*
|
2012-01-25 |
2022-11-30 |
Chiesi Farm Spa |
Formulacija suvog praha koja sadrži kortikosteroid i beta-adrenergik, za primenu inhalacijom
|
US20150010527A1
(en)
|
2012-02-01 |
2015-01-08 |
Protalix Ltd. |
Dnase i polypeptides, polynucleotides encoding same, methods of producing dnase i and uses thereof in therapy
|
CA2865972C
(fr)
|
2012-02-29 |
2022-01-04 |
Pulmatrix, Inc. |
Poudres seches pouvant etre inhalees
|
MX355299B
(es)
|
2012-03-13 |
2018-04-11 |
Respivert Ltd |
Inhibidores de cinasa de fosfoinositida 3 cristalina.
|
CA2869849A1
(fr)
|
2012-04-13 |
2013-10-17 |
Glaxosmithkline Intellectual Property Development Limited |
Particules agregees comprenant des particules de medicament nanoparticulaires de bromure d'umeclidinium, de trifenatate de vilanterol et de furoate de fluticasone
|
WO2014007771A2
(fr)
|
2012-07-05 |
2014-01-09 |
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi |
Compositions d'inhalation comprenant un antagoniste du récepteur muscarinique
|
US10111957B2
(en)
*
|
2012-07-05 |
2018-10-30 |
Arven Ilac Snayi ve Ticaret A.S. |
Inhalation compositions comprising glucose anhydrous
|
CN109846862A
(zh)
|
2012-10-25 |
2019-06-07 |
通用医疗公司 |
治疗阿尔茨海默病及相关疾病的组合疗法
|
US11052202B2
(en)
|
2012-11-07 |
2021-07-06 |
Chiesi Farmaceutici S.P.A. |
Drug delivery device for the treatment of patients with respiratory diseases
|
US9757395B2
(en)
|
2012-12-20 |
2017-09-12 |
Otitopic Inc. |
Dry powder inhaler and methods of use
|
US9757529B2
(en)
|
2012-12-20 |
2017-09-12 |
Otitopic Inc. |
Dry powder inhaler and methods of use
|
BR112015017784A2
(pt)
|
2013-01-28 |
2017-07-11 |
Incozen Therapeutics Pvt Ltd |
método para tratar distúrbios autoimunes, respiratórios e inflamatórios por inalação de n-óxido de roflumilast
|
GB201305825D0
(en)
|
2013-03-28 |
2013-05-15 |
Vectura Ltd |
New use
|
JP6505079B2
(ja)
|
2013-03-29 |
2019-04-24 |
アレクシオン ファーマシューティカルズ, インコーポレイテッド |
補体c5を標的とする治療薬の血清半減期を増加させるための組成物及び方法
|
EP3607941A1
(fr)
|
2013-04-30 |
2020-02-12 |
Otitopic Inc. |
Formulations de poudre sèche et procédés d'utilisation
|
US10525005B2
(en)
|
2013-05-23 |
2020-01-07 |
The General Hospital Corporation |
Cromolyn compositions and methods thereof
|
EP2821061B1
(fr)
*
|
2013-07-01 |
2017-12-20 |
Arven Ilac Sanayi Ve Ticaret A.S. |
Nouvelle formulation pour inhalation
|
PL3019153T3
(pl)
*
|
2013-07-11 |
2019-02-28 |
Chiesi Farmaceutici S.P.A. |
Preparat proszkowy zawierający środek antycholinergiczny, kortykosteroid i środek beta-adrenergiczny do podawania wziewnego
|
EP3052092A2
(fr)
*
|
2013-10-02 |
2016-08-10 |
Vectura Limited |
Procédé et appareil
|
US9427376B2
(en)
*
|
2013-10-10 |
2016-08-30 |
Chiesi Farmaceutici S.P.A. |
Process for preparing pharmaceutical formulations for inhalation comprising a high-dosage strength active ingredient
|
CN110305095A
(zh)
|
2013-10-22 |
2019-10-08 |
综合医院公司 |
色甘酸衍生物以及成像和治疗的相关方法
|
NZ631007A
(en)
|
2014-03-07 |
2015-10-30 |
Alexion Pharma Inc |
Anti-c5 antibodies having improved pharmacokinetics
|
US9554992B2
(en)
|
2014-06-09 |
2017-01-31 |
Chiesi Farmaceutici S.P.A. |
Inhalation particles comprising a combination of an anticholinergic, a corticosteroid and a beta-adrenergic
|
TR201407010A2
(tr)
|
2014-06-16 |
2015-12-21 |
Arven Ilac Sanayi Ve Ticaret Anonim Sirketi |
Vilanterol formülasyonları.
|
EP2957552B1
(fr)
|
2014-06-16 |
2020-01-22 |
Arven Ilac Sanayi Ve Ticaret A.S. |
Formulations de vilanterol
|
WO2016005443A1
(fr)
*
|
2014-07-09 |
2016-01-14 |
Arven Ilac Sanayi Ve Ticaret A.S. |
Procédé pour la préparation de formulations à inhaler
|
US20170304459A1
(en)
|
2014-10-10 |
2017-10-26 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for inhalation delivery of conjugated oligonucleotide
|
CN107106641B
(zh)
|
2014-10-31 |
2021-12-21 |
葛兰素史密斯克莱知识产权发展有限公司 |
粉末制剂
|
RU2693201C1
(ru)
*
|
2015-06-23 |
2019-07-01 |
Шлюмберже Текнолоджи Б.В. |
Распознание расклинивающего агента с помощью мобильного устройства
|
US11224594B2
(en)
*
|
2015-09-16 |
2022-01-18 |
Philip Morris Products S.A. |
Nicotine formulations and methods of making and using the same
|
DK3620176T3
(da)
|
2015-11-16 |
2021-09-20 |
Chiesi Farm Spa |
Fremgangsmåde til fremstilling af en tørpulverformulering omfattende et anticholinergikum, et corticosteroid og et beta-adrenergikum
|
HUE056402T2
(hu)
|
2015-11-16 |
2022-02-28 |
Chiesi Farm Spa |
Eljárás antikolinerg szert, kortikoszteroidot és béta-adrenerg szert tartalmazó száraz porkészítmény elõállítására
|
MX2018007512A
(es)
|
2015-12-24 |
2018-09-17 |
Philip Morris Products Sa |
Capsula de particula de nicotina.
|
US20190240194A1
(en)
|
2016-08-31 |
2019-08-08 |
The General Hospital Corporation |
Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases
|
BR112019023386A2
(pt)
*
|
2017-05-11 |
2020-06-16 |
Chiesi Farmaceutici S.P.A. |
Processo para preparar uma formulação em pó para inalação para uso em um inalador de pó seco
|
US10786450B2
(en)
|
2017-05-11 |
2020-09-29 |
Chiesi Farmaceutici S.P.A. |
Process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
|
US10583085B2
(en)
|
2017-05-17 |
2020-03-10 |
Chiesi Farmaceutici S.P.A. |
Carrier particles for dry powder formulations for inhalation
|
CN111133006A
(zh)
|
2017-07-14 |
2020-05-08 |
西托姆克斯治疗公司 |
抗cd166抗体及其用途
|
CN111107788B
(zh)
*
|
2017-07-26 |
2023-12-19 |
深圳帧观德芯科技有限公司 |
具有空间扩展性x射线源的x射线成像系统
|
BR112020001703B1
(pt)
|
2017-07-27 |
2024-01-02 |
Alexion Pharmaceuticals, Inc |
Solução aquosa estável compreendendo um anticorpo anti-c5, método para produção desta solução, uso da mesma para tratar uma condição associada ao complemento e kit terapêutico compreendendo a mesma
|
WO2019060604A1
(fr)
|
2017-09-20 |
2019-03-28 |
Teva Branded Pharmaceutical Products R&D, Inc. |
Médicament inhalable
|
EP3684338A4
(fr)
|
2017-09-22 |
2021-06-23 |
Otitopic Inc. |
Compositions de poudre sèche contenant du stéarate de magnésium
|
WO2019060797A1
(fr)
|
2017-09-22 |
2019-03-28 |
Teva Branded Pharmaceutical Products R&D, Inc. |
Procédé de fabrication de poudres à inhaler
|
US10786456B2
(en)
|
2017-09-22 |
2020-09-29 |
Otitopic Inc. |
Inhaled aspirin and magnesium to treat inflammation
|
WO2019067708A1
(fr)
*
|
2017-09-27 |
2019-04-04 |
Teva Branded Pharmaceutical Products R&D, Inc. |
Procédé pour diminuer la taille de particules
|
KR20210071943A
(ko)
*
|
2018-07-02 |
2021-06-16 |
더 제너럴 하스피탈 코포레이션 |
크로몰린 소듐 및 α-락토스의 분말화된 제형
|
US11813360B2
(en)
|
2018-07-27 |
2023-11-14 |
Chiesi Farmaceutici S.P.A. |
Carrier particles for dry powder formulations for inhalation
|
KR20210042412A
(ko)
|
2018-09-06 |
2021-04-19 |
주식회사 이노파마스크린 |
천식 또는 파킨슨병 치료를 위한 방법 및 조성물
|
CN112969490B
(zh)
|
2018-10-30 |
2024-07-12 |
奇斯药制品公司 |
用于向机械辅助呼吸患者施用药物的设备
|
WO2020123691A2
(fr)
|
2018-12-12 |
2020-06-18 |
Kite Pharma, Inc |
Récepteurs antigéniques chimériques et récepteurs de lymphocytes t et méthodes d'utilisation
|
BR112021021775A2
(pt)
|
2019-04-29 |
2022-01-04 |
Insmed Inc |
Composições de pó seco de pró-fármacos de treprostinil e métodos de uso destas
|
EP4034079A1
(fr)
|
2019-09-24 |
2022-08-03 |
Chiesi Farmaceutici S.p.A. |
Nouvelles particules de support pour formulations de poudre sèche pour inhalation
|
KR20230005268A
(ko)
|
2020-04-24 |
2023-01-09 |
밀레니엄 파머슈티컬스 인코퍼레이티드 |
항-cd19 항체 및 이의 용도
|
US20230277524A1
(en)
|
2020-05-22 |
2023-09-07 |
Trailhead Biosystems Inc. |
Combination therapy for treatment of viral infections
|
CN112451509B
(zh)
*
|
2020-12-19 |
2023-03-07 |
沈阳药科大学 |
一种川丁特罗吸入粉雾剂及其制备方法
|
EP4320149A1
(fr)
|
2021-04-09 |
2024-02-14 |
Takeda Pharmaceutical Company Limited |
Anticorps ciblant le facteur d du complément et leurs utilisations
|
IL307939A
(en)
|
2021-04-26 |
2023-12-01 |
Millennium Pharm Inc |
Anti-CLEC12A antibodies and uses thereof
|
AU2022266583A1
(en)
|
2021-04-26 |
2023-10-19 |
Millennium Pharmaceuticals, Inc. |
Anti-adgre2 antibodies and uses thereof
|
TW202330612A
(zh)
|
2021-10-20 |
2023-08-01 |
日商武田藥品工業股份有限公司 |
靶向bcma之組合物及其使用方法
|
CN118475343A
(zh)
|
2021-12-21 |
2024-08-09 |
凯西制药公司 |
填充在具有改善的耐湿性的吸入器中的干粉制剂
|
WO2023117967A1
(fr)
|
2021-12-21 |
2023-06-29 |
Chiesi Farmaceutici S.P.A. |
Formulations en poudre sèche remplies dans un inhalateur présentant une résistance à l'humidité améliorée
|
WO2023150747A1
(fr)
|
2022-02-07 |
2023-08-10 |
Insmed Incorporated |
Compositions de poudre sèche de bédaquiline et de sels et leurs méthodes d'utilisation
|
WO2024062007A1
(fr)
|
2022-09-22 |
2024-03-28 |
Chiesi Farmaceutici S.P.A. |
Inhalateur à capsule pour l'administration d'un inhibiteur de phosphodiestérase-4
|